NeoGenomics Management
Management criteria checks 2/4
NeoGenomics' CEO is Chris Smith, appointed in Aug 2022, has a tenure of 1.75 years. total yearly compensation is $11.67M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.47% of the company’s shares, worth €7.86M. The average tenure of the management team and the board of directors is 1.6 years and 3.3 years respectively.
Key information
Chris Smith
Chief executive officer
US$11.7m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.5% |
| Management average tenure | 1.6yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$84m |
| Dec 31 2023 | US$12m | US$1m | -US$88m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$115m |
| Mar 31 2023 | n/a | n/a | -US$126m |
| Dec 31 2022 | US$15m | US$346k | -US$144m |
Compensation vs Market: Chris's total compensation ($USD11.67M) is above average for companies of similar size in the German market ($USD1.61M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Smith (60 yo)
1.8yrs
Tenure
US$11,665,946
Compensation
Mr. Christopher Michael Smith, also known as Chris, serves as Chief Executive Officer at NeoGenomics Laboratories, Inc. since August 2022. He serves as Director at NeoGenomics Laboratories, Inc. since 2023...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$11.67m | 0.47% $ 7.9m | |
| Chief Financial Officer | 1.4yrs | US$3.55m | 0.098% $ 1.6m | |
| President of Advanced Diagnostics | 2.3yrs | US$2.37m | 0.10% $ 1.7m | |
| President & COO of Informatics | 1.4yrs | US$4.69m | 0.081% $ 1.3m | |
| Chief Commercial Officer | 1.5yrs | US$3.01m | 0.066% $ 1.1m | |
| Chief Accounting Officer | less than a year | no data | 0.012% $ 200.7k | |
| Vice President of Investor Relations & Communications | no data | no data | no data | |
| Executive VP of Business Development | 2.1yrs | no data | 0.027% $ 455.0k | |
| Chief Compliance Officer | 2.1yrs | no data | no data | |
| Chief Medical Officer | 3.3yrs | no data | no data | |
| Chief Culture Officer | 1.3yrs | no data | no data | |
| Director of Clinical Science | no data | no data | no data |
1.6yrs
Average Tenure
52yo
Average Age
Experienced Management: NG9's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$11.67m | 0.47% $ 7.9m | |
| Independent Director | 3.8yrs | US$317.50k | 0.016% $ 266.4k | |
| Independent Director | 9.6yrs | US$313.45k | 0.051% $ 849.8k | |
| Independent Chair of the Board | 8.9yrs | US$365.00k | 0.044% $ 733.0k | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Director | less than a year | US$276.23k | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Director | 6.8yrs | US$309.20k | 0.019% $ 323.0k | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board & Independent Director | 8.9yrs | US$305.00k | 0.084% $ 1.4m | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data |
3.3yrs
Average Tenure
62yo
Average Age
Experienced Board: NG9's board of directors are considered experienced (3.3 years average tenure).